Indietro

Tonix Pharmaceuticals Holding Corp

Ticker: TNXP ISIN: US8902608392
Aggiungi al portafoglio Analisi del portafoglio in 2min
Stock Small-cap High beta
Capitalizzazione
190,19 Mln $
P/E
0,06
Forward P/E
0,00
Profit margin
0,00%
Revenue growth QoQ
16,60%
Beta
1,82
13,64 $ -0,15%
Prezzo al 2026-08-26 · NASDAQ

Performance per periodo

Rendimenti cumulativi
1 Month +37,22%
6 Months -5,47%
1 Year -57,61%
5 Years -87,49% p.a.-100,00%
10 Years -67,41% p.a.-100,00%
Since inception -53,67% p.a.-100,00%
Rendimenti per anno
YTD -12,68%
2025 -52,67%
2024 -97,42%
2023 -83,59%
2022 -96,61%
2021 -47,06%

Key stats

Market cap
190,19 Mln
P/E
0,06
Beta
1,82
52-week range
6.76 - 72.00
50-day MA
22,34
200-day MA
26,61
Section 1

Business overview

Company profile data from fundamentals.

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat and prevent human disease. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as immunology, infectious disease, and rare disease product candidates. The company's products pipeline include TNX-102 SL (cyclobenzaprine HCl sublingual tablet), for the management of fibromyalgia; and is being developed to prevent and treat acute stress reaction, posttraumatic stress disorder, Alzheimer's disease, alcohol use disorder, and multi-site pain associated with Long COVID. It also develops TNX-1300, a double-mutant cocaine esterase, which is in Phase 2 clinical trials for the treatment of cocaine intoxication; and TNX-1900, an intranasal potentiated oxytocin for the treatment of binge eating disorder, adolescent obesity, and bone health in pediatric autism, as well as for social anxiety disorder. In addition, the company develops TNX-1500, an Fc-modified humanized monoclonal antibody indicated to prevent organ transplant rejection, as well as to treat autoimmune conditions; TNX-1700, a recombinant Trefoil Factor Family 2 fusion protein for the treatment of gastric and colorectal cancers; TNX-801 that is in the pre-IND development stage for protection against smallpox and mpox; and TNX-1800, a live virus vaccine for SARS-CoV-2. Its rare disease portfolio consists of TNX-2900, an intranasal potentiated oxytocin to treat for Prader-Willi syndrome. The company has collaboration agreement with Bilthoven Biologicals to advance TNX-801 and Makana Therapeutics, Inc. to study TNX-1500 for human-compatible organs and cells for the treatment of organ failure. Tonix Pharmaceuticals Holding Corp. is headquartered in Chatham, New Jersey.

Sector Healthcare
Industry Biotechnology
Country United States
Exchange NASDAQ
Section 2

Financial quality

Above-average volatility

Profitability and balance-sheet quality indicators from reported fundamentals.

Profitability

ROE -64,99%
ROA -35,94%
Profit margin 0,00%
Operating margin -10,05%
PEG ratio 0,00
Revenue/share TTM 1,68
Revenue TTM 10,30 Mln
EBITDA -97,46 Mln
Gross profit TTM 3,53 Mln
Beta 1,82

Valuation

Trailing P/E 0,06
Forward P/E 0,00
P/B 0,98
P/S 22,05
EV/EBITDA 0,94
EV/Revenue 3,63
Section 3

Earnings

Earnings metrics from company highlights and earnings datasets.

EPS estimate (current year) -10,30
Quarterly earnings growth 0,00%
Revenue TTM 10,30 Mln
Reported quarters 55
Section 4

Dividends & corporate actions

Dividend and split fields from fundamentals.

Forward annual div. yield 0,00%
Split factor 1:100
Last split date 2025-02-05
Section 5

Ownership / analyst view

Institutional ownership and analyst estimate fields when available.

Analyst

Analyst target price 67,67 $
Analyst rating 5

Ownership & short interest

Shares outstanding 11,78 Mln
Shares float 11,77 Mln
Institutional ownership 17,79%
Insider ownership 3,40%
Short ratio 2,19
Short % of float 15,99%

Details

Instrument metadata and source update timestamps.

Symbol TNXP
Name Tonix Pharmaceuticals Holding Corp
Asset type STOCK
Exchange NASDAQ
Currency USD
ISIN US8902608392
Country USA
Code + exchange TNXP.NASDAQ
Fundamentals updated 2025-12-16

Le informazioni fornite su questa piattaforma hanno solo scopo informativo e non devono essere considerate consulenza finanziaria o di investimento. Insightfolio non fornisce consulenza d'investimento, raccomandazioni personalizzate o indicazioni relative all'acquisto, alla detenzione o alla vendita di strumenti finanziari. Gli strumenti e i contenuti sono destinati esclusivamente a finalita educative e non sono adattati alle circostanze individuali, alle esigenze finanziarie o agli obiettivi personali.

Insightfolio non si assume alcuna responsabilita per l'accuratezza, la completezza o l'affidabilita delle informazioni presentate. Gli utenti sono gli unici responsabili della verifica delle informazioni e dell'assunzione di decisioni indipendenti basate sulla propria ricerca e su un'attenta valutazione. L'uso della piattaforma non deve sostituire la consulenza di professionisti finanziari qualificati.

Gli investimenti comportano rischi. Gli utenti devono essere consapevoli che il valore degli investimenti puo variare e che i rendimenti passati non sono indicativi di risultati futuri. Le decisioni di investimento devono basarsi sugli obiettivi finanziari personali, sulla tolleranza al rischio e su una valutazione indipendente delle informazioni rilevanti.

Insightfolio non approva ne garantisce l'idoneita di alcun prodotto finanziario, titolo o strategia specifica. Eventuali proiezioni, previsioni o scenari ipotetici presentati sulla piattaforma hanno solo scopo illustrativo e non costituiscono garanzia di risultati futuri.

Accedendo ai servizi, alle informazioni o ai contenuti offerti da Insightfolio, gli utenti riconoscono e accettano i presenti termini di esclusione di responsabilita. Se non accetti questi termini, ti invitiamo a non utilizzare la piattaforma.

Instrument logos provided by Elbstream.